Abstract:We chose hepcidin and its related factors as evaluating indicators to determine the degrees of iron overload in myelodysplastic syndromes (MDS) patients. A total of 73 patients and 28 healthy volunteers were enrolled in this study. We performed enzyme-linked immunosorbent assay to measure both bone marrow and peripheral blood serum hepcidin. Real-time quantitative polymerase chain reaction was used to determine the gene expression of growth differentiation factor 15 and twisted gastrulation 1. Serum ferritin (SF), C-reactive protein (CRP), and erythropoietin were measured by routine standard laboratory assays. CD4(+) and CD19(+) lymphocytes and Th polarization were detected by flow cytometry. Twenty-four MDS patients were measured their cardiac and liver iron deposition levels through magnetic resonance imaging (MRI) T2* examination. No significant difference was found between the bone marrow hepcidin levels and peripheral blood hepcidin levels (P = 0.134). Stratified according to different World Health Organization subtypes, refractory anemia with ringed sideroblasts patients had the lowest hepcidin levels (105.40 ± 5.13 ng/ml), while refractory anemia with excess blasts-1 had the highest levels (335.71 ± 25.16 ng/ml). Stratified according to International Prognostic Scoring System and WHO Classification-based Prognostic Scoring System, there was a significant difference of hepcidin levels between low-risk group and high-risk group in two systems, respectively (P = 0.033 and 0.009). The hepcidin levels of CD4(+) high-expression group were demonstrated higher than the normal expression groups (P = 0.02), but the CD19(+) high-expression group did not show the same result (P = 0.206). Meanwhile, patients with a Th1 polarization trend had a high level of hepcidin versus normal group (P < 0.001). Liver iron concentration (LIC) measured by MRI T2* had a closer correlation (r = 0.582, P < 0.001) to hepcidin than serum ferritin, by stepwise regression. C-reactive protein and LIC seemed to be the key determinants of hepcidin, by multivariate regression. Inflammation plays an important role in the regulation of hepcidin expression. T-lymphocyte activation and Th polarization trend might participate in the regulatory mechanism partly. The capability of organ iron load assessment of MRI T2* seems better than that of SF. It seems that hepcidin with CRP and LIC measured by MRI T2* are potential indicators of iron overload in MDS patients.

Recent progress in diagnosis applications of hepcidin in human disorders

Advance in Hepcidin

Hepcidin: A Promising Therapeutic Target for Iron Disorders: A Systematic Review.

Research Progress in Iron Biomarkers: a Review

Physiological and Pathophysiological Mechanisms of Hepcidin Regulation: Clinical Implications for Iron Disorders

Hepcidin as a Potential Biomarker for the Diagnosis of Anemia

Progress in Relationship between Infection of Helicobacter Pylori and Iron Deficiency Anemia

Iron metabolism and iron disorders revisited in the hepcidin era

LC-MS/MS method for hepcidin-25 measurement in human and mouse serum: clinical and research implications in iron disorders

Deregulation of proteins involved in iron metabolism in hepcidin-deficient mice

Hepcidin-Ferroportin Interaction Controls Systemic Iron Homeostasis

In-depth review: is hepcidin a marker for the heart and the kidney?

Development of a novel immunoassay for the iron regulatory peptide hepcidin

Serum Hepcidin in Haemodialysis Patients: Associations with Iron Status and Microinflammation.

Role of hepcidin in murine brain iron metabolism

Case studies: iron

Distinct Iron Deposition Profiles of Liver Zones in Various Models with Iron Homeostasis Disorders.

Hepatic Hepcidin Protects Against Polymicrobial Sepsis in Mice by Regulating Host Iron Status.

Relationship Between Iron Overload Caused by Abnormal Hepcidin Expression and Liver Disease: A Review

The Evaluation of Iron Overload Through Hepcidin Level and Its Related Factors in Myelodysplastic Syndromes.